Erzofri is a drug owned by Luye Innomind Pharma (shijiazhuang) Co Ltd. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 24, 2039. Details of Erzofri's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11666573 | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
Sep, 2039
(13 years from now) | Active |
| US12128049 | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
Oct, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Erzofri's patents.
Latest Legal Activities on Erzofri's Patents
Given below is the list of recent legal activities going on the following patents of Erzofri.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification | 29 Oct, 2024 | US12128049 |
| Mail Patent eGrant Notification | 29 Oct, 2024 | US12128049 |
| Recordation of Patent Grant Mailed | 29 Oct, 2024 | US12128049 |
| Patent Issue Date Used in PTA Calculation | 29 Oct, 2024 | US12128049 |
| Patent eGrant Notification | 29 Oct, 2024 | US12128049 |
| Recordation of Patent eGrant | 29 Oct, 2024 | US12128049 |
| Email Notification | 09 Oct, 2024 | US12128049 |
| Issue Notification Mailed | 09 Oct, 2024 | US12128049 |
| Dispatch to FDC | 26 Sep, 2024 | US12128049 |
| Application Is Considered Ready for Issue | 26 Sep, 2024 | US12128049 |
US patents provide insights into the exclusivity only within the United States, but
Erzofri is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Erzofri's family patents as well as insights into
ongoing legal events
on those patents.
Erzofri's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Erzofri's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 24, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Erzofri Generic API suppliers:
Paliperidone Palmitate is the generic name for the brand Erzofri. 1 company has already filed for the generic of Erzofri. Check out the entire list of companies who have already received approval for Erzofri's generic
Alternative Brands for Erzofri
There are several other brand drugs using the same active ingredient (Paliperidone Palmitate) as Erzofri. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Janssen Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Paliperidone Palmitate, Erzofri's active ingredient. Check the complete list of approved generic manufacturers for Erzofri
About Erzofri
Erzofri is a drug owned by Luye Innomind Pharma (Shijiazhuang) Co Ltd. Erzofri uses Paliperidone Palmitate as an active ingredient. Erzofri was launched by Innomind in 2024.
Approval Date:
Erzofri was approved by FDA for market use on 26 July, 2024.
Active Ingredient:
Erzofri uses Paliperidone Palmitate as the active ingredient. Check out other Drugs and Companies using Paliperidone Palmitate ingredient
Dosage:
Erzofri is available in suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 117MG/0.75ML (117MG/0.75ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 78MG/0.5ML (78MG/0.5ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 156MG/ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 39MG/0.25ML (39MG/0.25ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 234MG/1.5ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 351MG/2.25ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |